Literature DB >> 17326351

Early postoperative pain following Epi-LASIK and photorefractive keratectomy: a prospective, comparative, bilateral study.

Luis F Torres1, Cristhian Sancho, Bryan Tan, Karina Padilla, David J Schanzlin, Arturo S Chayet.   

Abstract

PURPOSE: To compare postoperative pain associated with epi-LASIK versus photorefractive keratectomy (PRK).
METHODS: This prospective observer-masked randomized study included 40 eyes of 20 patients with myopia and astigmatism who received epi-LASIK (Moria Epi-K) in one eye and PRK in the contralateral eye. Corneal ablation was done using the NIDEK EC-5000 excimer laser. Patients were seen at days 1, 3, and 6 to rate their pain via three measuring tools: 1) a global subjective rating, 2) a 10-cm visual analog scale, and 3) an 11-point numeric scale of pain.
RESULTS: On postoperative day 1, 19 of 20 patients reported pain in both eyes. Using the global subjective rating scale, patients reported more pain for those eyes treated by PRK. Although clinically relevant, this difference was not statistically significant (P = .56). Based on the 11-point numeric scale of pain and visual analog scale, mean pain scores were similar for both groups. On day 3, using the global subjective rating scale, 11 of 12 patients who had pain reported more in the epi-LASIK treated eye (P = .0005). In addition, epi-LASIK eyes demonstrated higher mean pain scores based on the other two scales (visual analog scale, P = .045 and 11-point numeric scale of pain, P = .023). Only 6 patients reported minimal pain on day 6. It was more frequently reported and slightly more marked in epi-LASIK eyes, but did not reach statistical significance.
CONCLUSIONS: Epi-LASIK and PRK have similar pain on postoperative day 1, but epi-LASIK demonstrated statistically more pain than PRK on days 3 and 6.

Entities:  

Mesh:

Year:  2007        PMID: 17326351     DOI: 10.3928/1081-597X-20070201-04

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  7 in total

1.  Comparison of clinical results between flap-on and flap-off techniques of epithelial-laser in situ keratomileusis in correction of low to moderate myopia in eyes with thin corneas.

Authors:  Aziz Shaher; Yahia Al-Gassaly; Horia Alansy; Tawfik Alkhatib
Journal:  Saudi J Ophthalmol       Date:  2012-06-18

2.  Subjective pain, visual recovery and visual quality after LASIK, EpiLASIK (flap off) and APRK - a consecutive, non-randomized study.

Authors:  Christos Skevas; Toam Katz; Lars Wagenfeld; Gisbert Richard; Stephan Linke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-25       Impact factor: 3.117

3.  Early postoperative pain and visual outcomes following epipolis-laser in situ keratomileusis and photorefractive keratectomy.

Authors:  Jae-Hyung Kim; Jooeun Lee; Jae Yong Kim; Hungwon Tchah
Journal:  Korean J Ophthalmol       Date:  2010-06-05

4.  One-step transepithelial topography-guided ablation in the treatment of myopic astigmatism.

Authors:  Aleksandar Stojanovic; Shihao Chen; Xiangjun Chen; Filip Stojanovic; Jia Zhang; Ting Zhang; Tor Paaske Utheim
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

5.  Temporal evolution of the biological response to laser-induced refractive index change (LIRIC) in rabbit corneas.

Authors:  Kaitlin T Wozniak; Sam C Butler; Xu He; Jonathan D Ellis; Wayne H Knox; Krystel R Huxlin
Journal:  Exp Eye Res       Date:  2021-04-20       Impact factor: 3.770

6.  Survey of Ehlers-Danlos Patients' ophthalmic surgery experiences.

Authors:  Anita Louie; Catherine Meyerle; Clair Francomano; Divya Srikumaran; Farhan Merali; Jefferson J Doyle; Kraig Bower; Lara Bloom; Michael V Boland; Nicholas Mahoney; Yassine Daoud; Eric L Singman
Journal:  Mol Genet Genomic Med       Date:  2020-01-27       Impact factor: 2.183

7.  Sodium Channel Blockers Modulate Abnormal Activity of Regenerating Nociceptive Corneal Nerves After Surgical Lesion.

Authors:  Carolina Luna; Kamila Mizerska; Susana Quirce; Carlos Belmonte; Juana Gallar; María Del Carmen Acosta; Víctor Meseguer
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-01-04       Impact factor: 4.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.